Disinfectant containing botanical antibacterial agent and preparation method thereof

Abstract

The invention relates to the field of disinfectants, in particular to a disinfectant containing a botanical antibacterial agent and a preparation method of the disinfectant, and the disinfectant is prepared from the following components in parts by mass: 40-50 parts of an oil phase, 40-50 parts of a water phase and 5-6 parts of a film forming solution, according to the invention, compounding is carried out according to a specific ratio, the problems of water solubility and dispersibility of active components are solved by utilizing a self-microemulsion system, and meanwhile, the film-forming liquid prepared from a natural polymer material is introduced, so that a long-acting slow-release protective film can be formed after use, and compared with the prior art, the disinfectant prepared by the invention has the advantages of wide antibacterial spectrum, high stability and low cost. The plant disinfectant can effectively kill bacteria and enveloped and non-enveloped viruses, is long in acting time, has excellent slow release performance and good skin compatibility, solves the problems of poor stability and short time of a traditional plant disinfectant, has the characteristics of being green, safe and environment-friendly, and is worthy of popularization and application. Wide application prospects are realized in the fields of medical treatment and public health, public health and epidemic prevention, home nursing and the like.

Description

Technical Field

[0001] This invention relates to the field of disinfectants, and more particularly to a disinfectant containing a plant-derived antibacterial agent and its preparation method. Background Technology

[0002] Plant-derived antibacterial agents refer to natural products extracted from plants that have the activity of inhibiting or killing microorganisms. They mainly include compounds such as alkaloids, flavonoids, volatile oils, and organic acids. Disinfectants with these as the main active ingredients belong to the category of bio-derived disinfectants. They have significant characteristics such as wide availability, good biocompatibility, environmental friendliness, and low likelihood of inducing drug resistance in microorganisms. Therefore, they show broad application prospects in fields such as medical and health care, public health and epidemic prevention, food processing, home care, and disinfection of infant and toddler products.

[0003] With consumers increasingly concerned about potential skin irritation, environmental pollution, and residual toxicity from chemical disinfectants, the development of safe and efficient plant-based disinfectants has become an important direction for technological development in the industry.

[0004] In existing technologies, traditional disinfectants contain only a single plant-derived antibacterial agent, resulting in a narrow antibacterial spectrum and limited efficacy. At the same time, some active ingredients, such as volatile oils, are chemically unstable and easily degraded by light, heat, and oxygen. Furthermore, most plant-derived antibacterial agents have poor water solubility, and direct application in aqueous disinfection systems can easily lead to stratification or precipitation, severely limiting their practical application effectiveness. In addition, conventional plant-derived disinfectants have a short antibacterial duration after use, making it difficult to meet the application requirements for long-term protection, and their inactivation effect against non-enveloped viruses and other difficult-to-kill microorganisms also needs to be improved.

[0005] Therefore, based on the relevant technologies mentioned above, there is an urgent need to develop a disinfectant containing plant-derived antibacterial agents and its preparation method. Summary of the Invention

[0006] In view of this, the purpose of this invention is to provide a disinfectant containing plant-derived antibacterial agents and its preparation method, so as to solve the problems of narrow antibacterial spectrum, poor stability, low water solubility, short duration of action and weak virus killing in the prior art.

[0007] To achieve the above objectives, the present invention provides a disinfectant containing a plant-derived antibacterial agent and a method for preparing the same.

[0008] A disinfectant containing a plant-derived antibacterial agent, comprising the following components in parts by weight: 40-50 parts oil phase, 40-50 parts aqueous phase, and 5-6 parts film-forming solution;

[0009] The oil phase is composed of microcapsule powder, alkyl glycosides, magnolia bark extract and polyglycerol fatty acid esters;

[0010] The aqueous phase consists of dandelion extract, 1,3-butanediol and deionized water;

[0011] The film-forming solution is composed of chitosan quaternary ammonium salt, pullulan polysaccharide, and dipotassium glycyrrhizate.

[0012] Preferably, the preparation steps of the microcapsule powder are as follows:

[0013] Step A1: Add β-cyclodextrin to deionized water, heat to 50-60℃, stir at 60-100 rpm for 10-20 minutes, and after stirring is complete, cool to 35-45℃ to obtain a saturated β-cyclodextrin solution.

[0014] Step A2: Add cinnamon essential oil to a saturated β-cyclodextrin solution, stir at 300-500 rpm, heat to 35-45℃, increase the stirring speed to 1000-1400 rpm, stir for 2-4 hours, after stirring is complete, cool to 3-5℃, let stand for 20-24 hours, filter, wash, and dry to obtain microcapsule powder.

[0015] To address the technical shortcomings of cinnamon essential oil and other plant volatile oils being easily oxidized and volatile, this invention controls the inclusion temperature, stirring speed, and inclusion time to allow cinnamon essential oil molecules to enter the hollow structure of β-cyclodextrin, forming a stable inclusion complex. Furthermore, the wall material barrier effect of β-cyclodextrin effectively prevents active ingredients such as cinnamaldehyde from degrading upon contact with light, heat, and oxygen, significantly extending the shelf life of the disinfectant. In addition, converting the liquid essential oil into a solid powder facilitates uniform mixing with other active ingredients such as magnolia bark extract, avoiding stratification issues during formulation. Simultaneously, the inclusion complex slowly releases cinnamon essential oil upon contact with water, endowing the disinfectant with sustained antibacterial properties.

[0016] Preferably, the mass ratio of β-cyclodextrin to deionized water in step A1 is 0.8-1.2:1;

[0017] The mass ratio of cinnamon essential oil to β-cyclodextrin saturated solution in step A2 is 0.1-0.15:1.

[0018] Preferably, the preparation steps of the aqueous phase are as follows:

[0019] Add dandelion extract to deionized water, heat to 35-45℃, stir at 200-300 rpm for 10-20 minutes, add citric acid to adjust the pH to 5.5-6.5, add 1,3-butanediol as a humectant, and stir for 5-15 minutes to obtain the aqueous phase. Preferably,

[0020] Preferably, the mass ratio of the dandelion extract, deionized water and 1,3-butanediol is 1:8-12:0.4-0.6.

[0021] Preferably, the preparation steps of the oil phase are as follows:

[0022] Add the Magnolia officinalis extract and microcapsule powder to a flask, heat to 35-45℃, stir at 60-100 rpm for 15-25 minutes, increase the temperature to 45-55℃, increase the stirring speed to 80-120 rpm, add polyglycerol fatty acid ester and alkyl glycoside, increase the stirring speed to 300-500 rpm, stir for 30-40 minutes, and after stirring is complete, the oil phase is obtained.

[0023] By subjecting the oil and aqueous phases to high-pressure shearing, a nanoemulsion with uniform particle size is formed. Simultaneously, polyglycerol fatty acid esters act as lipophilic emulsifiers, while alkyl glycosides act as hydrophilic emulsifiers. Their synergistic effect significantly reduces the surface tension of the oil phase droplets, enabling them to spontaneously form microemulsions upon contact with water. Therefore, this not only solves the problem of precipitation of lipid-soluble components such as magnolol and cinnamaldehyde in aqueous disinfectants, but also significantly enhances the affinity between antibacterial components and microbial cell membranes due to the large specific surface area brought about by the nano-sized particles. This improves the bactericidal efficacy per unit concentration, achieving a synergistic antibacterial effect.

[0024] Preferably, the mass ratio of the Magnolia officinalis extract, microcapsule powder, polyglycerol fatty acid ester and alkyl glycoside is 0.62-0.64:1:0.52-0.53:0.3-0.32.

[0025] Preferably, the preparation steps of the film-forming solution are as follows:

[0026] Add chitosan quaternary ammonium salt to deionized water, heat to 55-65℃, stir at 400-500 rpm for 20-30 minutes, add pullulan polysaccharide and dipotassium glycyrrhizate, cool to 45-55℃, reduce the stirring speed to 300-400 rpm, stir for 10-20 minutes, after stirring is complete, add citric acid, adjust the pH to 5.8-6.4, filter through a 100-mesh filter cloth to obtain the film-forming solution;

[0027] By using chitosan quaternary ammonium salt as a cationic polymer film-forming material, it not only possesses excellent antibacterial activity but can also be evenly spread on object surfaces or skin. After drying, it forms a transparent, breathable, and well-adhesive protective film. At the same time, pullulan polysaccharide, as a film-forming aid, can improve the flexibility and integrity of the film, preventing the film layer from cracking and peeling. Dipotassium glycyrrhizate has anti-inflammatory and soothing effects, which can neutralize the slight irritation that plant-derived antibacterial agents may cause. By mixing it with an emulsion, it can form a functional film after the water evaporates when it is applied to the object surface, continuously releasing antibacterial components.

[0028] The mass ratio of chitosan quaternary ammonium salt, deionized water, pullulan polysaccharide and dipotassium glycyrrhizate is 1:1.2-1.4:0.8-1.2:0.52-0.54.

[0029] A method for preparing a disinfectant containing a plant-derived antibacterial agent, the specific steps of which are as follows:

[0030] Step S1: Add the oil phase to the aqueous phase, heat to 35-40℃, rotate at 300-500 rpm, stir for 15-25 minutes, place in a high-pressure homogenizer, pressurize to 20-25 MPa, homogenize 1-3 times, and after homogenization is complete, obtain the emulsion.

[0031] Step S2: Add the emulsion to the film-forming solution, heat to 30-40℃, stir at 200-300 rpm for 20-30 minutes, add deionized water, reduce the speed to 150-250 rpm, stir for 10-20 minutes, after stirring is complete, let stand for 20-30 minutes to obtain the disinfectant.

[0032] Preferably, the mass ratio of the oil phase to the water phase in step S1 is 1:1.4-1.8;

[0033] The mass ratio of the emulsion, film-forming solution and deionized water in step S2 is 1:0.05-0.07:0.015-0.025.

[0034] The beneficial effects of this invention are:

[0035] This invention provides a disinfectant containing plant-derived antibacterial agents and its preparation method. The invention involves compounding Magnolia officinalis extract, cinnamon essential oil microcapsules treated with inclusion technology, and dandelion extract in a specific ratio. A self-microemulsion system is used to address the water solubility and dispersibility issues of the active ingredients. Simultaneously, a film-forming liquid composed of natural polymer materials is introduced, enabling the formation of a long-lasting, sustained-release protective film after use. Compared with existing technologies, the disinfectant prepared by this invention has a broad antibacterial spectrum, high stability, and can effectively kill bacteria and both enveloped and non-enveloped viruses. It also exhibits a long duration of action, excellent sustained-release properties, and good skin compatibility. This solves the problems of poor stability and short duration of action of traditional plant-based disinfectants, and is characterized by its green safety and environmental friendliness, showing broad application prospects in medical and health fields, public health and epidemic prevention, and home care. Attached Figure Description

[0036] To more clearly illustrate the technical solutions in this invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only for this invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0037] Figure 1 This is a bar chart showing the stability test results in this invention;

[0038] Figure 2 This is a bar chart showing the sustained-release performance test results in this invention;

[0039] Figure 3 This is a bar chart of Staphylococcus aureus in the antibacterial performance test of this invention;

[0040] Figure 4 This is a bar chart showing the results of Escherichia coli in the antibacterial performance test of this invention;

[0041] Figure 5 This is a bar chart showing the results of Candida albicans in the antibacterial performance test of this invention;

[0042] Figure 6 This is a bar chart showing the antiviral performance test results in this invention. Detailed Implementation

[0043] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments.

[0044] Example 1: The preparation steps of a microcapsule powder are as follows:

[0045] S1: Add 80g of β-cyclodextrin to 100g of deionized water, heat to 50℃, stir at 100rpm for 10min, and after stirring is complete, cool to 45℃ to obtain a saturated β-cyclodextrin solution.

[0046] S2: Add 10g of cinnamon essential oil to 100g of saturated β-cyclodextrin solution, stir at 300rpm, heat to 45℃, increase the speed to 1000rpm, stir for 4h, after stirring is complete, cool to 3℃, let stand for 24h, filter, wash, and dry to obtain microcapsule powder.

[0047] Example 2: The preparation steps of a microcapsule powder are as follows:

[0048] S1: Add 90g of β-cyclodextrin to 100g of deionized water, heat to 55℃, stir at 80rpm for 15min, and after stirring is complete, cool to 40℃ to obtain a saturated β-cyclodextrin solution.

[0049] S2: Add 13g of cinnamon essential oil to 100g of saturated β-cyclodextrin solution, stir at 400rpm, heat to 40℃, increase the speed to 1200rpm, stir for 3h, after stirring is complete, cool to 4℃, let stand for 22h, filter, wash, and dry to obtain microcapsule powder.

[0050] Example 3: The preparation steps of a microcapsule powder are as follows:

[0051] S1: Add 120g of β-cyclodextrin to 100g of deionized water, heat to 60℃, stir at 60rpm for 20min, and after stirring is complete, cool to 35℃ to obtain a saturated β-cyclodextrin solution.

[0052] S2: Add 15g of cinnamon essential oil to 100g of saturated β-cyclodextrin solution, stir at 500rpm, heat to 35℃, increase the speed to 1400rpm, stir for 2h, after stirring is complete, cool to 5℃, let stand for 20h, filter, wash, and dry to obtain microcapsule powder.

[0053] Example 4: The preparation steps of an oil phase are as follows:

[0054] Add 62g of Magnolia officinalis extract and 100g of microcapsule powder (Example 1) to a flask, heat to 35°C, stir at 100 rpm for 15 min, increase the temperature to 55°C, increase the stirring speed to 80 rpm, add 52g of polyglycerol fatty acid ester and 30g of alkyl glycoside, increase the stirring speed to 300 rpm, stir for 40 min, and after stirring is complete, obtain the oil phase.

[0055] Example 5: The preparation steps of an oil phase are as follows:

[0056] Add 63g of Magnolia officinalis extract and 100g of microcapsule powder (Example 2) to a flask, heat to 40°C, stir at 80 rpm for 20 min, increase the temperature to 50°C, increase the stirring speed to 100 rpm, add 52.5g of polyglycerol fatty acid ester and 31g of alkyl glycoside, increase the stirring speed to 400 rpm, stir for 35 min, and after stirring is complete, obtain the oil phase.

[0057] Example 6: The preparation steps of an oil phase are as follows:

[0058] Add 64g of Magnolia officinalis extract and 100g of microcapsule powder (Example 3) to a flask, heat to 45°C, stir at 60 rpm for 25 min, increase the temperature to 45°C, increase the stirring speed to 120 rpm, add 53g of polyglycerol fatty acid ester and 32g of alkyl glycoside, increase the stirring speed to 300 rpm, stir for 40 min, and after stirring is complete, obtain the oil phase.

[0059] Example 7: The preparation steps of an oil phase are as follows:

[0060] 62g of Magnolia officinalis extract, 100g of microcapsule powder (Example 1), and 10g of lemongrass oil were added to a flask. The mixture was heated to 35°C and stirred at 100 rpm for 15 minutes. The temperature was then increased to 55°C and the stirring speed was increased to 80 rpm. 52g of polyglycerol fatty acid ester and 30g of alkyl glycoside were added. The stirring speed was increased to 300 rpm and stirred for 40 minutes. Once stirring was complete, the oil phase was obtained.

[0061] Example 8: The preparation steps of an aqueous phase are as follows:

[0062] Add 100g of dandelion extract to 800g of deionized water, heat to 35℃, stir at 300rpm for 10min, add citric acid, adjust pH to 5.5-6.5, add 40g of humectant 1,3-butanediol, stir for 15min to obtain the aqueous phase.

[0063] Example 9: The preparation steps of an aqueous phase are as follows:

[0064] Add 100g of dandelion extract to 1000g of deionized water, heat to 40℃, stir at 250rpm for 15min, add citric acid, adjust pH to 5.5-6.5, add 50g of humectant 1,3-butanediol, stir for 10min to obtain the aqueous phase.

[0065] Example 10: The preparation steps of an aqueous phase are as follows:

[0066] Add 100g of dandelion extract to 1200g of deionized water, heat to 45℃, stir at 200rpm for 20min, add citric acid, adjust pH to 5.5-6.5, add 60g of humectant 1,3-butanediol, stir for 5min to obtain the aqueous phase.

[0067] Example 11: The preparation steps of an aqueous phase are as follows:

[0068] Add 100g of dandelion extract to 800g of deionized water, heat to 35℃, stir at 300rpm for 10min, add 30g of aloe vera extract and 25g of propylene glycol, stir for 20min, add citric acid, adjust pH to 5.5-6.5, add 40g of humectant 1,3-butanediol, stir for 15min to obtain the aqueous phase.

[0069] Example 12: The preparation steps of a film-forming solution are as follows:

[0070] Add 100g of chitosan quaternary ammonium salt to 120g of deionized water, heat to 55℃, stir at 500rpm for 20min, add 80g of pullulan polysaccharide and 52g of dipotassium glycyrrhizate, cool to 45℃, reduce the stirring speed to 400rpm, stir for 10min, after stirring is complete, add citric acid, adjust the pH to 5.8-6.4, filter through a 100-mesh filter cloth to obtain the film-forming solution.

[0071] Example 13: The preparation steps of a film-forming solution are as follows:

[0072] Add 100g of chitosan quaternary ammonium salt to 130g of deionized water, heat to 60℃, stir at 450rpm for 25min, add 100g of pullulan polysaccharide and 53g of dipotassium glycyrrhizate, cool to 50℃, reduce the stirring speed to 350rpm, stir for 15min, after stirring is complete, add citric acid, adjust the pH to 5.8-6.4, filter through a 100-mesh filter cloth to obtain the film-forming solution.

[0073] Example 14: The preparation steps of a film-forming solution are as follows:

[0074] Add 100g of chitosan quaternary ammonium salt to 140g of deionized water, heat to 65℃, stir at 400rpm for 30min, add 120g of pullulan polysaccharide and 54g of dipotassium glycyrrhizate, cool to 45℃, reduce the stirring speed to 400rpm, stir for 10min, after stirring is complete, add citric acid, adjust the pH to 5.8-6.4, filter through a 100-mesh filter cloth to obtain the film-forming solution.

[0075] Example 15: The preparation steps of a film-forming solution are as follows:

[0076] Add 100g of chitosan quaternary ammonium salt to 120g of deionized water, heat to 55℃, stir at 500rpm for 20min, add 80g of pullulan, 52g of dipotassium glycyrrhizate and 8g of vitamin E acetate, cool to 45℃, reduce the stirring speed to 400rpm and stir for 10min. After stirring is complete, add citric acid and adjust the pH to 5.8-6.4. Filter through a 100-mesh filter cloth to obtain the film-forming solution.

[0077] Example 16: A method for preparing a disinfectant containing a plant-derived antibacterial agent

[0078] S1: Add 100g of oil phase (Example 4) to 140g of aqueous phase (Example 8), heat to 35°C, rotate at 500 rpm, stir for 15 min, place in a high-pressure homogenizer, pressurize to 25 MPa, homogenize once, and after homogenization is complete, obtain emulsion;

[0079] S2: Add 100g of emulsion to 5g of film-forming solution (Example 12), heat to 30°C, stir at 300rpm for 20min, add 1.5g of deionized water, reduce the speed to 250rpm, stir for 10min, after stirring is complete, let stand for 30min to obtain disinfectant.

[0080] Example 17: A method for preparing a disinfectant containing a plant-derived antibacterial agent

[0081] S1: Add 100g of oil phase (Example 5) to 160g of aqueous phase (Example 9), heat to 37°C, rotate at 400 rpm, stir for 20 min, place in a high-pressure homogenizer, pressurize to 23 MPa, homogenize twice, and after homogenization is completed, obtain emulsion;

[0082] S2: Add 100g of emulsion to 6g of film-forming solution (Example 13), heat to 35°C, stir at 250rpm for 25min, add 7g of deionized water, reduce the speed to 200rpm, stir for 15min, after stirring is complete, let stand for 25min to obtain disinfectant.

[0083] Example 18: A method for preparing a disinfectant containing a plant-derived antibacterial agent

[0084] S1: Add 100g of oil phase (Example 6) to 180g of aqueous phase (Example 10), heat to 40°C, rotate at 300 rpm, stir for 25 min, place in a high-pressure homogenizer, pressurize to 20 MPa, homogenize 3 times, and after homogenization is completed, obtain emulsion;

[0085] S2: Add 100g of emulsion to 7g of film-forming solution (Example 14), heat to 40°C, stir at 200rpm for 30min, add 2.5g of deionized water, reduce the speed to 150rpm, stir for 20min, after stirring is complete, let stand for 20min to obtain disinfectant.

[0086] Example 19: A method for preparing a disinfectant containing a plant-derived antibacterial agent

[0087] S1: Add 100g of oil phase (Example 7) to 140g of aqueous phase (Example 11), heat to 35°C, rotate at 500 rpm, stir for 15 min, place in a high-pressure homogenizer, pressurize to 25 MPa, homogenize once, and after homogenization is completed, obtain emulsion;

[0088] S2: Add 100g of emulsion to 5g of film-forming solution (Example 15), heat to 30°C, stir at 300rpm for 20min, add 1.5g of deionized water, reduce the speed to 250rpm, stir for 10min, after stirring is complete, let stand for 30min to obtain disinfectant.

[0089] Comparative Example 1:

[0090] Compared with Example 16, this comparative example did not add polyglycerol fatty acid esters and alkyl glycosides during the preparation of the oil phase. All other steps and parameters were the same, and will not be repeated here. The final disinfectant was obtained.

[0091] Comparative Example 2:

[0092] This comparative example differs from Example 16 only in that the "microcapsules" are replaced with "cinnamon essential oil". All other steps and parameters are the same, and will not be repeated here. The final disinfectant is obtained.

[0093] Comparative Example 3:

[0094] Compared with Example 16, this comparative example did not add a film-forming liquid during the preparation of a disinfectant containing a plant-derived antibacterial agent. All other steps and parameters were the same, and will not be repeated here. The final disinfectant was obtained.

[0095] Comparative Example 4:

[0096] Compared with Example 16, this comparative example did not add microcapsules during the preparation of the oil phase. All other steps and parameters were the same, and will not be repeated here. The final disinfectant was obtained.

[0097] Performance testing:

[0098] Stability test (reference) Figure 1 )

[0099] The test was conducted using a high-performance liquid chromatograph, in accordance with the GB / T 38499-2020 testing standard.

[0100] 1. Take 20 mL of each of the disinfectants from Examples 16-19 and Comparative Examples 1-4, shake well, accurately pipette 1.0 mL into a 10 mL brown volumetric flask, dilute to the mark with methanol, shake well, filter through a 0.45 μm organic microporous membrane, discard about 1 mL of the initial filtrate, and take the subsequent filtrate into a brown sample vial for detection by high performance liquid chromatography.

[0101] 2. Chromatographic conditions: Column: C18 reversed-phase column (250mm×4.6mm, 5μm), mobile phase: methanol-water (65:35 v / v), flow rate: 1.0mL / min, detection wavelength: 280nm, column temperature: 30℃, feed volume: 20μL, run time: 10-15min.

[0102] 3. Place the sample in a 54℃ constant temperature incubator for 14 days, remove the sample, allow it to return to room temperature, and test it according to the above method. Repeat the test three times and take the average value.

[0103] 4. Calculation:

[0104]

[0105]

[0106] Table 1. Stability test results of the examples and comparative examples

[0107]

[0108] Particle size testing

[0109] The test was conducted using a Malvern Zetasizer Nano ZS90 laser particle size analyzer, in accordance with the GB / T 29022-2012 test standard.

[0110] Take 0.1 mL of each of the disinfectants from Examples 16-19 and Comparative Examples 1-4, dilute with deionized water to 10 mL, mix well, inject into a cuvette, and test with a laser particle size analyzer. Set up a blank control test, that is, add an equal amount of deionized water to the cuvette and measure Z-Average (nm) and PDI.

[0111] Table 2. Particle size test results of the examples and comparative examples

[0112]

[0113] Sustained-release performance test (reference) Figure 2 )

[0114] Staphylococcus aureus

[0115] 1. Preparation of bacterial suspension: Inoculate the preserved bacterial strain onto nutrient agar slants and incubate at 37℃ for 24 h. After 2-3 consecutive subcultures, wash off the bacterial growth with 0.03 mol / L PBS buffer and adjust the bacterial suspension concentration to 1×10⁻⁶ using a McFarland turbidimetric tube. 8 -5×10 8 CFU / mL, for later use;

[0116] Neutralizing agent: PBS buffer (pH 7.2-7.4) containing 0.5% lecithin and 1% Tween 80, autoclaved at 121°C for 20 min before use;

[0117] 2. Take 0.1 mL of each of the disinfectants from Examples 16-19 and Comparative Examples 1-4, and coat them evenly on the surface of a sterile stainless steel carrier, ensuring that the coating is uniform and free of bubbles. Dry at 25±2℃ to form a film to obtain the carrier product.

[0118] 3. Place the carrier product in a constant temperature incubator, heat it to 25℃, relative humidity 50%, and leave it for 24 hours. Then, take it out, add 10mL of neutralizing agent, shake and elute for 2 minutes to obtain the eluent.

[0119] 4. Add 1 mL of elution buffer to a nutrient agar plate. After the agar solidifies, incubate in a 37°C incubator for 48 hours and then count the colonies.

[0120] Control experiment: Take blank sterile carriers that have not been coated with disinfectant, and perform elution and viable count in the same way.

[0121] 5. Calculation:

[0122]

[0123] N0: Average colony count of negative control vector (CFU / vector);

[0124] N t : The average number of colonies on the vector after the test sample has been treated (CFU / vector).

[0125] Table 3. Results of sustained-release performance tests for the examples and comparative examples

[0126]

[0127] Antibacterial performance test (reference) Figure 3-5 )

[0128] Staphylococcus aureus, Escherichia coli and Candida albicans were used

[0129] 1. Preparation of bacterial suspension: Staphylococcus aureus, Escherichia coli, and Candida albicans were inoculated onto nutrient agar slants. Staphylococcus aureus and Escherichia coli were cultured at 37°C for 24 h, and Candida albicans was cultured at 37°C for 48 h. The suspension was subcultured 2-3 times. The suspension was eluted with 5 mL of PBS buffer and transferred to sterile test tubes. The bacterial suspension concentration was adjusted using McFarland turbidimetric tubes to achieve a bacterial count of approximately 1 × 10⁻⁶. 8 -5×10 8 CFU / mL, then add PBS buffer and dilute to 1×10⁻⁶. 4 -5×10 4 CFU / mL, to obtain bacterial suspension;

[0130] 2. Take 4 mL of each of the disinfectants from Examples 16-19 and Comparative Examples 1-4, add 1.0 mL of bacterial suspension, place in a constant temperature water bath at 20℃±1℃, and allow to act for 2 min, 5 min, and 10 min respectively. After reaching the set time, immediately take 1.0 mL of the sample-bacterial suspension mixture and add it to a 9.0 mL neutralizing agent test tube, and mix thoroughly.

[0131] 3. Take 1 mL of the neutralized sample solution and pour it into a nutrient agar plate. After the agar solidifies, incubate it in a 37℃ constant temperature incubator: culture bacteria for 48 h and Candida albicans for 72 h, count the colonies, and take the average value.

[0132] 4. Positive control group: Sterile hard water was used instead of disinfectant sample. After mixing with bacterial suspension, samples were taken immediately for viable bacteria counting as the initial bacterial count control.

[0133] Neutralizing agent control: Mix the neutralizing agent with the bacterial suspension, and count the viable bacteria after 10 minutes of contact.

[0134] Culture medium control: Sterile PBS was used instead of bacterial suspension for pour culture;

[0135] 5. Calculation:

[0136]

[0137] N0: Average colony count of the positive control (CFU / vector);

[0138] N t : Average colony count (CFU / mL) at each time point after disinfectant treatment.

[0139] Table 4. Antibacterial performance test results of the examples and comparative examples

[0140]

[0141] Antiviral performance test (reference) Figure 6 )

[0142] A carbon dioxide incubator was used in accordance with the GB / T 38502-2020 testing standard.

[0143] Virus strains: Influenza virus H1N1, feline calicivirus;

[0144] Host cells: MDCK cells, CRFK cells;

[0145] Cell growth medium:

[0146] MDCK cells: DMEM medium containing 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin;

[0147] CRFK cells: MEM medium containing 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin;

[0148] Cell maintenance solution:

[0149] The corresponding culture medium contains 2% fetal bovine serum (FBS), 100 U / mL penicillin, and 100 μg / mL streptomycin;

[0150] The influenza virus maintenance solution needs to be supplemented with 2 μg / mL TPCK-treated trypsin.

[0151] 1. Seed MDCK and CRFK cells separately into cell culture flasks containing their respective growth media and incubate at 37°C in a 5% CO2 incubator. When the cells reach monolayer confluence, passage them using trypsin-EDTA digestion every 2-3 days. After digestion, seed the cells into 96-well cell culture plates, adding 100 μL of cell suspension (approximately 2 × 10⁶ cells / well) to each well. 5(cells / mL), and cultured in a 37℃, 5% CO2 incubator until a monolayer of cells is formed for later use;

[0152] 2. Preparation of virus suspension: The virus strain was inoculated into a monolayer of the corresponding host cells (MDCK cells for influenza virus, CRFK cells for feline calicivirus). After adsorption at 37°C for 1 hour, maintenance medium was added and cultured for a longer period. When approximately 75% of the cells showed cytopathic effects, the virus culture was harvested, and the mixture was subjected to three freeze-thaw cycles. After centrifugation at 4°C and 3000 rpm for 15 minutes, the supernatant was collected and diluted with maintenance medium to approximately 10⁻⁶. 6 -10 7 TCID 50 / mL;

[0153] 3. Take 0.1 mL of the disinfectant from Examples 16-19 and Comparative Examples 1-4 respectively, add 0.1 mL of virus suspension, place in a water bath at 20℃±1℃ for 10 min, after the reaction is complete, add 0.8 mL of neutralizing agent, mix well, and neutralize for 10 min to obtain a mixed solution;

[0154] Positive control: 0.1 mL virus suspension, 0.1 mL maintenance solution;

[0155] Neutralizing agent control: 0.1 mL virus suspension, 0.1 mL neutralizing agent;

[0156] 4. Dilute the mixture 10 times with maintenance solution (10 -1 Up to 10 -6 Aspirate the cell growth medium from the 96-well plate, add 100 μL of sample-virus mixture of various dilutions to each well, and incubate at 37°C and 5% CO2 for 2 hours for adsorption. After adsorption, aspirate the inoculum, add 200 μL of cell maintenance medium to each well, and incubate at 37°C and 5% CO2. Culture the influenza virus for 3-5 days and the feline calicivirus for 3-4 days, and record the number of wells where CPE occurs.

[0157] 5. Viral titer (TCID) 50 )calculate:

[0158]

[0159] L: Logarithm of the highest dilution;

[0160] d: Logarithmic difference of dilution factors;

[0161] S: The sum of the proportions of positive wells for each dilution of CPE;

[0162] 6. Calculation of inactivation logarithmic value:

[0163]

[0164] in:

[0165] : Logarithmic viral titer of the positive control group;

[0166] Logarithmic value of virus titer after disinfectant treatment

[0167] Table 5. Antiviral performance test results of the examples and comparative examples

[0168]

[0169] Data Analysis:

[0170] As can be seen from Table 1, the disinfectant prepared by this invention has higher stability, smaller particle size, better sustained-release performance, stronger antibacterial effect and broader-spectrum antiviral activity.

[0171] In contrast, Comparative Example 1, due to the absence of polyglycerol fatty acid esters and alkyl glycosides in the oil phase preparation process, failed to form a self-microemulsion system. The average particle size increased significantly to 586.2 nm, and the PDI reached as high as 0.423. The system was prone to stratification and precipitation, and had poor water solubility. This is because polyglycerol fatty acid esters act as lipophilic emulsifiers, and alkyl glycosides act as hydrophilic emulsifiers. Only through their synergistic effect can the oil-water interfacial tension be effectively reduced to form a stable nanoemulsion. Without emulsifiers, the oil phase droplets cannot be effectively emulsified and dispersed.

[0172] Comparative Example 2, which only replaced the microcapsules with unencapsulated cinnamon essential oil, had a cinnamaldehyde retention rate of only 66.7% after heat storage, which was significantly lower than the 96% or more in the Example. This is because the cinnamon essential oil was not encapsulated with β-cyclodextrin, and the active ingredients such as cinnamaldehyde were directly exposed to the external environment, making it susceptible to oxidative degradation due to light, heat and oxygen. At the same time, the unencapsulated liquid essential oil had poor dispersibility in the system, which affected the stability of the antibacterial effect.

[0173] Comparative Example 3, due to the absence of a film-forming liquid in the disinfectant preparation process, resulted in a sterilization rate of 86.71% after 24 hours, which was significantly lower than the 99.9% or higher of the Example. This is because the film-forming system composed of chitosan quaternary ammonium salt and pullulan polysaccharide can form a functional protective film on the surface of objects and continuously release antibacterial components. Without the film-forming liquid, a long-lasting sustained-release barrier cannot be formed, and the antibacterial effect is significantly shortened.

[0174] Comparative Example 4, due to the absence of microcapsules in the oil phase preparation process, exhibited a significantly narrower antibacterial spectrum. Its 5-minute bactericidal rate against Candida albicans was only 98.85%, and its inactivation log value against feline calicivirus was only 2.2, far lower than the 4.0 or higher of the Example. This is because Magnolia officinalis extract and cinnamon essential oil have a synergistic effect, and only the combination of the two can achieve a broad-spectrum antibacterial and antiviral effect. Without cinnamon essential oil, Magnolia officinalis extract alone is insufficient to effectively kill Candida albicans and non-enveloped viruses.

[0175] Example 19 achieved optimal performance by adding lemongrass oil to the oil phase, aloe vera extract and propylene glycol to the aqueous phase, and vitamin E acetate to the film-forming solution. Its average particle size was only 98.6 nm, cinnamaldehyde retention was as high as 96.5%, the 24-hour sterilization rate remained at 99.95%, the inactivation log value against influenza virus reached 5.6, and the inactivation log value against feline calicivirus reached 4.5. This was because the active ingredients such as citral in lemongrass oil formed a ternary complex system with magnolia bark extract and cinnamon essential oil, further broadening the antibacterial spectrum and producing a synergistic effect. Aloe vera extract, rich in polysaccharides and amino acids, worked together with propylene glycol to enhance the moisturizing properties and skin compatibility of the aqueous phase. Vitamin E acetate, as a fat-soluble antioxidant, not only protected the active ingredients in the film-forming solution from oxidation but also enhanced the flexibility and stability of the film, thus comprehensively improving the overall performance of the disinfectant.

[0176] Those skilled in the art should understand that the discussion of any of the above embodiments is merely exemplary and is not intended to imply that the scope of the invention is limited to these examples; within the framework of the invention, the technical features of the above embodiments or different embodiments can also be combined, the steps can be implemented in any order, and there are many other variations of the different aspects of the invention as described above, which are not provided in detail for the sake of brevity.

[0177] This invention is intended to cover all such substitutions, modifications, and variations that fall within the broad scope of the appended claims. Therefore, any omissions, modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this invention should be included within the scope of protection of this invention.

Claims

1. A disinfectant containing a plant-derived antibacterial agent, characterized in that, It consists of the following components in parts by weight: 40-50 parts oil phase, 40-50 parts aqueous phase, and 5-6 parts film-forming solution; The oil phase is composed of microcapsule powder, alkyl glycosides, magnolia bark extract and polyglycerol fatty acid esters; The aqueous phase consists of dandelion extract, 1,3-butanediol and deionized water; The film-forming solution is composed of chitosan quaternary ammonium salt, pullulan polysaccharide, and dipotassium glycyrrhizate.

2. The disinfectant containing a plant-derived antibacterial agent according to claim 1, characterized in that, The preparation steps of the microcapsule powder are as follows: Step A1: Add β-cyclodextrin to deionized water, heat to 50-60℃, stir at 60-100 rpm for 10-20 minutes, and after stirring is complete, cool to 35-45℃ to obtain a saturated β-cyclodextrin solution. Step A2: Add cinnamon essential oil to a saturated β-cyclodextrin solution, stir at 300-500 rpm, heat to 35-45℃, increase the stirring speed to 1000-1400 rpm, stir for 2-4 hours, after stirring is complete, cool to 3-5℃, let stand for 20-24 hours, filter, wash, and dry to obtain microcapsule powder.

3. A disinfectant containing a plant-derived antibacterial agent according to claim 2, characterized in that, The mass ratio of β-cyclodextrin to deionized water in step A1 is 0.8-1.2:1; The mass ratio of cinnamon essential oil to β-cyclodextrin saturated solution in step A2 is 0.1-0.15:

1.

4. The disinfectant containing a plant-derived antibacterial agent according to claim 1, characterized in that, The preparation steps of the aqueous phase are as follows: Add dandelion extract to deionized water, heat to 35-45℃, stir at 200-300 rpm for 10-20 minutes, add citric acid, adjust pH to 5.5-6.5, add 1,3-butanediol as a humectant, stir for 5-15 minutes to obtain the aqueous phase.

5. A disinfectant containing a plant-derived antibacterial agent according to claim 4, characterized in that, The mass ratio of the dandelion extract, deionized water and 1,3-butanediol is 1:8-12:0.4-0.

6.

6. A disinfectant containing a plant-derived antibacterial agent according to claim 2, characterized in that, The preparation steps of the oil phase are as follows: Add the Magnolia officinalis extract and microcapsule powder to a flask, heat to 35-45℃, stir at 60-100 rpm for 15-25 minutes, increase the temperature to 45-55℃, increase the stirring speed to 80-120 rpm, add polyglycerol fatty acid ester and alkyl glycoside, increase the stirring speed to 300-500 rpm, stir for 30-40 minutes, and after stirring is complete, the oil phase is obtained.

7. A disinfectant containing a plant-derived antibacterial agent according to claim 6, characterized in that, The mass ratio of the Magnolia officinalis extract, microcapsule powder, polyglycerol fatty acid ester and alkyl glycoside is 0.62-0.64:1:0.52-0.53:0.3-0.

32.

8. A disinfectant containing a plant-derived antibacterial agent according to claim 1, characterized in that, The preparation steps of the film-forming solution are as follows: Add chitosan quaternary ammonium salt to deionized water, heat to 55-65℃, stir at 400-500 rpm for 20-30 minutes, add pullulan polysaccharide and dipotassium glycyrrhizate, cool to 45-55℃, reduce the stirring speed to 300-400 rpm, stir for 10-20 minutes, after stirring is complete, add citric acid, adjust the pH to 5.8-6.4, filter through a 100-mesh filter cloth to obtain the film-forming solution; The mass ratio of chitosan quaternary ammonium salt, deionized water, pullulan polysaccharide and dipotassium glycyrrhizate is 1:1.2-1.4:0.8-1.2:0.52-0.

54.

9. A method for preparing a disinfectant containing a plant-derived antibacterial agent according to any one of claims 1-8, characterized in that, The specific steps of the preparation method are as follows: Step S1: Add the oil phase to the aqueous phase, heat to 35-40℃, rotate at 300-500 rpm, stir for 15-25 minutes, place in a high-pressure homogenizer, pressurize to 20-25 MPa, homogenize 1-3 times, and after homogenization is complete, obtain the emulsion. Step S2: Add the emulsion to the film-forming solution, heat to 30-40℃, stir at 200-300 rpm for 20-30 minutes, add deionized water, reduce the speed to 150-250 rpm, stir for 10-20 minutes, after stirring is complete, let stand for 20-30 minutes to obtain the disinfectant.

10. A method for preparing a disinfectant containing a plant-derived antibacterial agent according to claim 9, characterized in that, The mass ratio of oil phase to water phase in step S1 is 1:1.4-1.8; The mass ratio of the emulsion, film-forming solution and deionized water in step S2 is 1:0.05-0.07:0.015-0.025.

Images